<DOC>
	<DOCNO>NCT02759094</DOCNO>
	<brief_summary>Prospective , open-label , multi-centre , single arm treatment trial evaluate safety effectiveness RefluxStop treatment GERD . The used medical device `` RefluxStop '' implantable single use sterile device ensure maintenance gastro oesophageal junction ( GEJ ) intra-abdominal position reduce eliminate GERD .</brief_summary>
	<brief_title>Evaluation Safety Effectiveness RefluxStop Device Management GERD</brief_title>
	<detailed_description>Prospective , open-label , multi-centre , single arm treatment trial evaluate safety effectiveness RefluxStop treatment GERD . The used medical device `` RefluxStop '' implantable single use sterile device ensure maintenance gastro oesophageal junction ( GEJ ) intra-abdominal position reduce eliminate GERD . The study plan include screening/baseline visit , surgical procedure phase hospital stay discharge , follow-up visit 6 week , 3 month 6 month device implantation . The study include part A ( 20 patient follow 6 week ) part B ( first 20 patient assess 3 month 6 month , remain 30 patient assessed week , 3 month , 6 month ) . An independent Safety Monitoring Board ( SMB ) review result first 20 patient 6 week . The Board also meet one month prior anticipate inclusion 50 patient order recommend whether increase sample size need safety documentation purpose .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Subject 's age &gt; = 18 year &lt; = 75 year Subject able undergo general anaesthesia suitable laparoscopic surgical candidate Subject willing able participate Subject provide write informed consent inform study procedure risk prior studyrelated event Subject document typical GERD symptom present &gt; 6 month respond PPIs antiGERD medication . Typical symptom GERD define heartburn , burn epigastric substernal pain Subject require daily PPI anti GERD medication Subject 24hour pH monitoring proven GERD perform take anti reflux medication discontinuation least 7 day prior test . Total distal oesophageal pH must &lt; = 4 &gt; = 4.5 % time 24hour monitoring Subject currently participate another study involve investigational drug device Subject history gastro oesophageal surgery , antireflux bariatric procedure Subject history endoscopic antireflux intervention Subject history suspicion oesophageal gastric cancer Subject history major psychiatric disorder Presence paraoesophageal hernia slide hernia &gt; 3cm determine endoscopy Presence oesophagitis grade C D accord Los Angeles classification Presence oesophageal dysmotility disorder limit sclerodermia , achalasia , Nutcracker oesophagus Presence oesophageal stricture stenosis Presence delay gastric empty Presence oesophageal gastric varies Subject body mass index ( BMI ) &gt; 35kg/m2 Female patient pregnant nursing Subjects unable comply protocol requirement Subjects limited life expectancy ( &lt; 3 year ) Intraoperative finding may preclude conduct study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>GERD</keyword>
	<keyword>Implantable medical device</keyword>
	<keyword>RefluxStop</keyword>
	<keyword>Reflux</keyword>
	<keyword>Gastroesophageal Reflux</keyword>
	<keyword>Laparoscopy</keyword>
	<keyword>pH-Monitoring</keyword>
	<keyword>PPI proton pump inhibitor</keyword>
</DOC>